UK markets closed

NVO Jan 2025 85.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.61000.0000 (0.00%)
As of 02:45PM EDT. Market open.
Full screen
Previous close0.6100
Open0.6500
Bid0.3900
Ask0.7800
Strike85.00
Expiry date2025-01-17
Day's range0.6100 - 0.6600
Contract rangeN/A
Volume4
Open interest351
  • Benzinga

    Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval

    On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition. Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss. Related: Chinese Generic O

  • Investor's Business Daily

    Is Eli Lilly Stock A Sell On A Rare Stumble In Obesity Treatment?

    Is Eli Lilly stock a buy after shares have leveraged a comeback following the acquisition of Morphic and positive weight-loss drug news?

  • Zacks

    Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

    Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.